DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-8.37%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.26B
AUM Growth
+$5.26B
(-21%)
Cap. Flow
-$544M
Cap. Flow
% of AUM
-10.34%
Top 10 Holdings %
Top 10 Hldgs %
53.77%
Holding
466
New
22
Increased
24
Reduced
24
Closed
360
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$87.7M |
| 2 |
Dynavax Technologies
DVAX
|
$66M |
| 3 |
Oscar Health
OSCR
|
$53.5M |
| 4 |
Legend Biotech
LEGN
|
$50.5M |
| 5 |
Indivior
INDV
|
$47.1M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$157M |
| 2 |
Kura Oncology
KURA
|
$106M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$64.6M |
| 4 |
Neurocrine Biosciences
NBIX
|
$62.1M |
| 5 |
WAY
Waystar Holding Corp
WAY
|
$60.8M |
Sector Composition
| 1 | Healthcare | 88.36% |
| 2 | Industrials | 0.23% |
| 3 | Consumer Staples | 0.01% |
| 4 | Energy | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
51
DELISTED
Chimerix, Inc.
CMRX
| $13.1M | 0.25% |
+3,771,342
| New | +$13.1M |
|
|
CON
52
Concentra Group Holdings Parent, Inc.
CON
$3.04B
| $12.9M | 0.24% |
650,000
| – | – |
|
|
ZBIO
53
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $12.8M | 0.24% |
1,562,942
| – | – |
|
|
ACCD
54
DELISTED
Accolade, Inc. Common Stock
ACCD
| $11.9M | 0.23% |
3,475,000
| – | – |
|
|
THRD
55
DELISTED
Third Harmonic Bio
THRD
| $10.5M | 0.2% |
+1,019,700
| New | +$10.5M |
|
56
Spyre Therapeutics
SYRE
$1.02B
| $10.5M | 0.2% |
+450,000
| New | +$10.5M |
|
57
Pulmonx
LUNG
$67.6M
| $10.4M | 0.2% |
+1,534,763
| New | +$10.4M |
|
58
Dyne Therapeutics
DYN
$1.92B
| $10.3M | 0.19% |
435,653
| – | – |
|
59
Neurogene
NGNE
$284M
| $10.2M | 0.19% |
+448,145
| New | +$10.2M |
|
60
Structure Therapeutics
GPCR
$1.14B
| $10.1M | 0.19% |
373,407
-471,000
| -56% | -$12.8M |
|
61
Perspective Therapeutics
CATX
$251M
| $9.37M | 0.18% |
2,938,754
+120,991
| +4% | +$386K |
|
62
Fate Therapeutics
FATE
$119M
| $5.87M | 0.11% |
3,555,871
| – | – |
|
63
Nkarta
NKTX
$149M
| $5.37M | 0.1% |
2,155,000
| – | – |
|
64
Corvus Pharmaceuticals
CRVS
$419M
| $5.35M | 0.1% |
+1,000,000
| New | +$5.35M |
|
65
CalciMedica
CALC
$45M
| $4.6M | 0.09% |
1,300,000
+300,000
| +30% | +$1.06M |
|
66
HilleVax
HLVX
$105M
| $3.9M | 0.07% |
1,882,654
| – | – |
|
|
OMIC
67
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $3.23M | 0.06% |
166,162
| – | – |
|
68
Annexon
ANNX
$225M
| $3M | 0.06% |
583,913
| – | – |
|
69
Alector
ALEC
$282M
| $2.02M | 0.04% |
1,066,962
+11,770
| +1% | +$22.2K |
|
|
70
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $1.32M | 0.03% |
92,787
| – | – |
|
71
BiomX
PHGE
$14.1M
| $1.31M | 0.02% |
1,787,610
| – | – |
|
72
Ventyx Biosciences
VTYX
$184M
| $1.17M | 0.02% |
534,737
-6,180,764
| -92% | -$13.5M |
|
73
Twist Bioscience
TWST
$1.57B
| $1.11M | 0.02% |
23,827
+403
| +2% | +$18.7K |
|
74
The Oncology Institute
TOI
$302M
| $1.04M | 0.02% |
3,360,052
| – | – |
|
|
QSIAW
75
Quantum-Si Incorporated Warrant
QSIAW
$75.2M
| $417K | 0.01% |
333,333
| – | – |
|